Last reviewed · How we verify

KLH-2109 — Competitive Intelligence Brief

KLH-2109 (KLH-2109) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium channel opener. Area: Cardiovascular.

marketed Potassium channel opener ATP-sensitive potassium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

KLH-2109 (KLH-2109) — Kissei Pharmaceutical Co., Ltd.. KLH-2109 is a potassium channel opener that relaxes vascular smooth muscle to reduce blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
KLH-2109 TARGET KLH-2109 Kissei Pharmaceutical Co., Ltd. marketed Potassium channel opener ATP-sensitive potassium channel
GLIMEPIRIDE + METFORMIN GLIMEPIRIDE + METFORMIN Sanofi marketed Sulfonylurea + biguanide combination ATP-sensitive potassium channel (Kir6.2/SUR1); mitochondrial respiratory chain complex I
Glimepiride/metformin fixed combination Glimepiride/metformin fixed combination Handok Inc. marketed Sulfonylurea/biguanide combination ATP-sensitive potassium channel (glimepiride); mitochondrial complex I / AMPK pathway (metformin)
metformin or sulfonylurea metformin or sulfonylurea Dr. Milan Gupta marketed Antidiabetic agents (biguanide and sulfonylurea) Metformin: AMP-activated protein kinase (AMPK) pathway; Sulfonylureas: ATP-sensitive potassium channel (KATP)
metformin/glimepiride combination metformin/glimepiride combination Laboratorios Silanes S.A. de C.V. marketed Biguanide/Sulfonylurea combination AMP-activated protein kinase (AMPK) pathway; ATP-sensitive potassium channels (KATP)
Levosimendan infusion Levosimendan infusion AHEPA University Hospital marketed Calcium sensitizer / inodilator Cardiac troponin C; ATP-sensitive potassium channels
"Metformin" and "Mitiglinide" "Metformin" and "Mitiglinide" Third Affiliated Hospital of Third Military Medical University marketed Antidiabetic combination (biguanide + meglitinide) Metformin: AMP-activated protein kinase (AMPK); Mitiglinide: ATP-sensitive potassium channel (KATP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium channel opener class)

  1. Kissei Pharmaceutical Co., Ltd. · 2 drugs in this class
  2. Astellas Pharma Inc · 1 drug in this class
  3. Cardurion Pharmaceuticals, Inc. · 1 drug in this class
  4. Dr. dr. Lili Legiawati, SpKK(K) · 1 drug in this class
  5. Eurofarma Laboratorios S.A. · 1 drug in this class
  6. GlaxoSmithKline · 1 drug in this class
  7. Allergan · 1 drug in this class
  8. Triple Hair Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). KLH-2109 — Competitive Intelligence Brief. https://druglandscape.com/ci/klh-2109. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: